In a recent update on Q BioMed, Inc. (OTCQB: QBIO), SeeThruEquity noted, among other topics, that the biomedical acceleration and development company’s FDA-approved radiopharmaceutical agent, SR89 (Strontium Chloride), is ahead of schedule and “revenue ready.” Q BioMed has initiated production of SR89 for the treatment of metastatic bone cancer and expects a commercial launch later this year. The company previously estimated it could generate more than $1 million in sales in its first year of commercialization, reaching more than $10 million in sales within 3-5 years. The SeeThruEquity analyst notes that SR89 has the potential for additional indications and a larger therapeutic market, which could result in “substantially greater revenues.
For more information, visit www.qbiomed.com
About Q BioMed Inc.
Q BioMed Inc. “Q” is a biomedical acceleration and development company. The company is focused on licensing and acquiring undervalued biomedical assets in the healthcare sector. Q is dedicated to be providing these target assets; strategic resources, developmental support, and expansion capital to ensure they meet their developmental potential, enabling them to provide products to patients in need.
NetworkNewsBreaks (NNB) provide a rapid summary of corporate news that caught the attention of NetworkNewsWire (NNW). NNB keeps you up-to-date on active US Public Companies complementary to NNW’s broader scope as a provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer